Supplementary Tables 1-6 from <i>MET</i>-Oncogenic and <i>JAK2</i>-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer

Supplementary Table 1. Characteristics of tumors and patients included in the analysis; Supplementary Table 2. List of antibodies and treatments used; Supplementary Table 3. Sequence of primers used for real-time quantitative PCR and size of amplified; Supplementary Table 4. Alterations at the indicated genes in lung cancer cell lines. cell carcinomas; SCLC, small Supplementary Table S5: RNA-sequencing report; Supplementary Table S6: List of genes from the MET-Activated (MET-Sign) and Interferon Treatment (IFN-